Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
NCT02959138
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Inflammatory Disease
Interventions
DRUG:
Lanraplenib.
Sponsor
Gilead Sciences